Compare Stocks → Investors Alert: The Next Big Thing in Weight Loss (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BLCMNASDAQ:MLNDNASDAQ:ONCYNASDAQ:OTICNASDAQ:SCPH Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLCMBellicum Pharmaceuticals$0.07-6.6%$0.08$0.06▼$1.31$727K1.3922,874 shs6,000 shsMLNDMillendo Therapeutics$3.71$4.00$0.92▼$16.95$70.65M0.481.52 million shs570,671 shsONCYOncolytics Biotech$1.06+2.9%$1.09$0.88▼$3.39$79.95M1.94400,927 shs294,183 shsOTICOtonomy$0.01$0.06$0.01▼$2.54$582K1.54937,525 shsN/ASCPHscPharmaceuticals$5.02-0.2%$5.49$4.63▼$12.75$180.97M0.08238,793 shs110,060 shs(Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLCMBellicum Pharmaceuticals0.00%0.00%-7.65%-53.83%-71.23%MLNDMillendo Therapeutics+1.92%-1.33%-6.31%-18.64%+112.00%ONCYOncolytics Biotech+1.98%+1.98%+4.05%-24.26%-14.88%OTICOtonomy0.00%0.00%0.00%0.00%-92.53%SCPHscPharmaceuticals+2.44%-9.86%-16.03%-21.34%-43.86%Investors Alert: The Next Big Thing in Weight Loss (Ad)History shows biotech breakthroughs like this can turn small investments into staggering fortunes for those with the foresight to get in early. I've isolated the small company behind it all...The profit window is closing - don't get left behind!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLCMBellicum PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AMLNDMillendo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AONCYOncolytics Biotech2.6499 of 5 stars3.55.00.00.02.90.00.6OTICOtonomyN/AN/AN/AN/AN/AN/AN/AN/ASCPHscPharmaceuticals4.036 of 5 stars3.51.00.04.33.31.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLCMBellicum PharmaceuticalsN/AN/AN/AN/AMLNDMillendo TherapeuticsN/AN/AN/AN/AONCYOncolytics Biotech3.00Buy$5.00371.70% UpsideOTICOtonomyN/AN/AN/AN/ASCPHscPharmaceuticals3.00Buy$19.33285.13% UpsideCurrent Analyst RatingsLatest OTIC, MLND, ONCY, BLCM, and SCPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/14/2024SCPHscPharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.002/14/2024ONCYOncolytics BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.001/19/2024ONCYOncolytics BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.001/12/2024ONCYOncolytics BiotechCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight1/4/2024ONCYOncolytics BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLCMBellicum Pharmaceuticals$1.50M0.48N/AN/A$0.23 per share0.33MLNDMillendo TherapeuticsN/AN/AN/AN/A$1.78 per shareN/AONCYOncolytics BiotechN/AN/AN/AN/A$0.27 per shareN/AOTICOtonomy$130K4.48N/AN/A$0.97 per share0.01SCPHscPharmaceuticals$13.59M13.32N/AN/A$1.04 per share4.83Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLCMBellicum Pharmaceuticals-$24.97MN/A0.00∞N/AN/AN/A-157.93%3/29/2024 (Estimated)MLNDMillendo Therapeutics-$36.41MN/A0.00∞N/AN/A-91.03%-72.44%N/AONCYOncolytics Biotech-$20.56M-$0.30N/AN/AN/AN/A-105.97%-72.80%5/3/2024 (Estimated)OTICOtonomy-$51.18M-$0.77N/A∞N/AN/A-137.86%-68.50%N/ASCPHscPharmaceuticals-$54.81M-$1.42N/AN/AN/A-403.22%-97.18%-49.59%5/8/2024 (Estimated)DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLCMBellicum PharmaceuticalsN/AN/AN/AN/AN/AMLNDMillendo TherapeuticsN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/AOTICOtonomyN/AN/AN/AN/AN/ASCPHscPharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLCMBellicum PharmaceuticalsN/A3.043.04MLNDMillendo TherapeuticsN/A6.396.39ONCYOncolytics BiotechN/A9.019.01OTICOtonomyN/A1.741.74SCPHscPharmaceuticals1.047.086.40OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLCMBellicum Pharmaceuticals4.93%MLNDMillendo TherapeuticsN/AONCYOncolytics Biotech6.82%OTICOtonomy41.23%SCPHscPharmaceuticals89.52%Insider OwnershipCompanyInsider OwnershipBLCMBellicum Pharmaceuticals10.30%MLNDMillendo TherapeuticsN/AONCYOncolytics Biotech0.10%OTICOtonomy1.09%SCPHscPharmaceuticals4.68%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBLCMBellicum Pharmaceuticals139.72 million8.72 millionNot OptionableMLNDMillendo Therapeutics1219.04 millionN/ANot OptionableONCYOncolytics Biotech2975.42 million75.35 millionNot OptionableOTICOtonomy5168.53 million67.78 millionOptionableSCPHscPharmaceuticals9636.05 million34.37 millionOptionableOTIC, MLND, ONCY, BLCM, and SCPH HeadlinesSourceHeadlineThose who invested in scPharmaceuticals (NASDAQ:SCPH) five years ago are up 62%finance.yahoo.com - March 27 at 9:26 AMscPharmaceuticals, Inc.: scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Updatefinanznachrichten.de - March 20 at 6:25 PMHC Wainwright Reaffirms Buy Rating for scPharmaceuticals (NASDAQ:SCPH)marketbeat.com - March 18 at 4:34 PMResearch Analysts Offer Predictions for scPharmaceuticals Inc.'s FY2028 Earnings (NASDAQ:SCPH)americanbankingnews.com - March 18 at 2:44 AMFY2026 EPS Estimates for scPharmaceuticals Inc. (NASDAQ:SCPH) Lifted by Leerink Partnrsamericanbankingnews.com - March 18 at 2:44 AMscPharmaceuticals Inc. (NASDAQ:SCPH) Q4 2023 Earnings Call Transcriptinsidermonkey.com - March 16 at 5:02 PMSCPH Apr 2024 5.000 putfinance.yahoo.com - March 16 at 2:28 AMBuy Rating Affirmed for scPharmaceuticals Amidst Revenue Surge and Solid Financial Footingmarkets.businessinsider.com - March 15 at 4:27 PMQ4 2023 scPharmaceuticals Inc Earnings Callfinance.yahoo.com - March 14 at 3:51 PMAnalysts Have Conflicting Sentiments on These Healthcare Companies: Neurocrine (NBIX), Jazz Pharmaceuticals (JAZZ) and scPharmaceuticals (SCPH)markets.businessinsider.com - March 14 at 10:50 AMStrong Buy Recommendation for scPharmaceuticals on Furoscix’s Successful Launch and Growth Prospectsmarkets.businessinsider.com - March 14 at 10:50 AMscPharmaceuticals Inc (SCPH) Reports Q4 and Full-Year 2023 Financials, Focusing on FUROSCIX Growthfinance.yahoo.com - March 13 at 6:18 PMscPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Updateglobenewswire.com - March 13 at 4:01 PMscPharmaceuticals Q4 2023 Earnings Previewmsn.com - March 12 at 8:33 PMCraig-Hallum Reaffirms Their Buy Rating on scPharmaceuticals (SCPH)markets.businessinsider.com - March 11 at 6:45 PMscPharmaceuticals Inc Registered Shs hosts conference call for investorsmarkets.businessinsider.com - March 9 at 1:38 PMscPharmaceuticals (SCPH) Set to Announce Earnings on Wednesdaymarketbeat.com - March 7 at 1:08 PMscPharmaceuticals to Announce Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, March 13, 2024globenewswire.com - March 6 at 4:01 PMscPharmaceuticals to Participate in Two Upcoming Investor Conferencesglobenewswire.com - February 28 at 4:01 PMscPharmaceuticals Stock (NASDAQ:SCPH), Short Interest Reportbenzinga.com - February 21 at 8:00 PMDelveInsight Business Research, LLP: Heart Failure Treatment Drug Market to Accelerate Immensely by 2032, Predicts DelveInsightfinanznachrichten.de - January 15 at 5:47 PMTop 10 stocks with the highest short interest on Wall Streetmsn.com - January 8 at 3:25 PMStrong Buy: scPharmaceuticals’ Furoscix Shows Robust Sales Growth and Solid Financial Healthmarkets.businessinsider.com - January 7 at 5:46 AMBuy Rating for scPharmaceuticals: Furoscix’s Market Traction and Growth Potential Drive Positive Valuationmarkets.businessinsider.com - January 5 at 11:23 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesHow to Invest in Artificial Intelligence in These Simple WaysMarch 7, 2024 1:08 PMView How to Invest in Artificial Intelligence in These Simple Ways5 Under-the-Radar Artificial Intelligence (AI) Stocks March 4, 2024 9:30 AMView 5 Under-the-Radar Artificial Intelligence (AI) Stocks Your Comprehensive Guide to Investing in Bank StocksMarch 1, 2024 10:41 AMView Your Comprehensive Guide to Investing in Bank StocksCathie Wood Likes UiPath Stock Over NVDA, Should You?March 5, 2024 7:00 AMView Cathie Wood Likes UiPath Stock Over NVDA, Should You?UiPath Cuts Q1 and Raises Full Year GuidanceMarch 26, 2024 7:41 AMView UiPath Cuts Q1 and Raises Full Year GuidanceAll Headlines Company DescriptionsBellicum PharmaceuticalsNASDAQ:BLCMBellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.Millendo TherapeuticsNASDAQ:MLNDAs of June 25, 2021, Millendo Therapeutics, Inc. was acquired by Tempest Therapeutics Inc., in a reverse merger transaction. Millendo Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in Ann Arbor, Michigan.Oncolytics BiotechNASDAQ:ONCYOncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.OtonomyNASDAQ:OTICOtonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.scPharmaceuticalsNASDAQ:SCPHscPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.